Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 5/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27888847 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNA5CHRNA7CHRNA4ACKR3 | |
| SCHEMBL13584651 | 0.89 | PMP22 (0.35) | CHRNB2CHRNA5CHRNA7CHRNA4ACKR3 | |
| SCHEMBL27888818 | 0.89 | PMP22 (0.35) | CHRNB2CHRNA5CHRNA7CHRNA4ACKR3 | |
| SCHEMBL27872429 | 0.82 | CHRNB2 (0.34) | CHRNB2CHRNA5CHRNA7CHRNA4ACKR3 | |
| SCHEMBL13585047 | 0.81 | ACE (0.35) | CHRNB2CHRNA5CHRNA7CHRNA4ACKR3 | |
| SCHEMBL1768599 | 0.78 | GRIK1 (0.36) | CHRNB2CHRNA5CHRNA7CHRNA4ACKR3 | |
| SCHEMBL13585045 | 0.76 | ALDH1A1 (0.34) | ACKR3CYP1A2CHRM3 | |
| SCHEMBL25660550 | 0.76 | CYP1A2 (0.45) | CHRNB2CHRNA5CHRNA7CHRNA4CYP1A2 | |
| SCHEMBL25662234 | 0.76 | CYP1A2 (0.45) | CHRNB2CHRNA5CHRNA7CHRNA4CYP1A2 | |
| SCHEMBL1768551 | 0.76 | CYP1A2 (0.35) | CHRNB2CHRNA5CHRNA7CHRNA4ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754038-B2 | Template-fixed peptidomimetics with CCR10 antagonistic activity | POLYPHOR AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| CN-102712676-A | Template-fixed peptidomimetics with CCR10 antagonistic activty | POLYPHOR AG | 2012-10-03 | — | — | CN | disclosed |
| WO-2011060832-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283168-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | CCR10, CCR1, CCRL2 | CHRNB2 2443/4885CHRNA5 1953/4885CHRNA7 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.